Valuation: StemRIM

Market Cap 18.68B 118M 105M 96.73M 87.85M 165M 11.17B 169M 1.15B 464M 5.89B 442M 433M P/E 2024
-13.6x
P/E 2025 -10.2x
Enterprise Value 11.68B 73.74M 65.88M 60.51M 54.96M 103M 6.98B 106M 722M 291M 3.69B 277M 271M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
46.29%
Yield 2024 *
-
Yield 2025 -
10-07 StemRIM Inc. Announces Patent Registration for Stem Cell Gene Therapy Technology SR-GT1 Aimed at Curative Treatment of Dystrophic Epidermolysis Bullosa in USA CI
09-25 StemRIM Inc. Announces Patent Registration In South Korea For Use Of Redasemtide As Additional Therapeutic Indication Of Cartilage Disorders CI
09-09 StemRIM Reports Earnings Results for the Full Year Ended July 31, 2026 CI
07-22 Stemrim Announces Patent Registration in Mexico for Redasemtide as Therapeutic Agent for Cartilage Disorders CI
07-08 StemRIM Inc. Announces Patent Registration For Stem Cell Gene Therapy Technology SR-GT1 Aimed At Curative Treatment Of Dystrophic Epidermolysis Bullosa In South Korea CI
06-17 StemRIM Announces Patent Registration for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders CI
06-16 StemRIM Inc Announces Patent Registration In Russia For Redasemtide As Therapeutic Drug For Fatty Liver And Non-Alcoholic Steatohepatitis CI
06-16 StemRIM to Register Russian Patent of Drug Candidate for Fatty Liver Disease MT
06-10 StemRIM Reports Earnings Results for the Nine Months Ended April 30, 2026 CI
05-12 Stemrim Inc. Announces Progress for Regeneration-Inducing Medicine Redasemtide CI
04-15 StemRIM Finishes Enrollment in Phase 1/2 Redasemtide Study MT
04-15 StemRIM Inc. Announces Completion of Patient Enrollment in Phase 1/2 InvestigatorInitiated Clinical Trial of Redasemtide for Patients with Ischemic Cardiomyopathy CI
03-11 StemRIM Reports Earnings Results for the Half Year Ended January 31, 2026 CI
1 day-3.60%
1 week-6.29%
Current month-3.60%
1 month-18.29%
3 months-55.03%
6 months-55.18%
Current year-49.05%
1 week 131
Extreme 131
149
1 month 131
Extreme 131
169
Current year 131
Extreme 131
368
1 year 131
Extreme 131
368
3 years 131
Extreme 131
735
5 years 131
Extreme 131
1,518
10 years 131
Extreme 131
1,518
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 01/10/2022
Chief Executive Officer 58 25/10/2023
President 56 01/04/2010
Director TitleAgeSince
Chairman 66 01/09/2026
Director/Board Member 58 01/03/2019
Director/Board Member 54 01/10/2019
Change 5-day change 1-year change 3-year change Capi.($)
-3.60%-6.29%-51.62%-80.47% 53.22M
-0.33%+10.02%+57.32%+148.40% 1,257B
-1.88%-0.78%+43.15%+76.18% 651B
-1.25%-0.07%+35.02%+102.37% 510B
-1.56%-2.01%+50.67%+64.81% 388B
-3.17%+1.28%+74.12%+38.93% 366B
-0.02%+2.11%+32.16%+57.79% 303B
-0.72%+7.32%+11.29%+33.98% 288B
-1.02%+3.34%+56.24%+71.54% 252B
-1.23%+6.26%+38.50%+107.18% 211B
Average -1.43%+3.51%+34.68%+62.07% 422.67B
Weighted average by Cap. -1.09%+5.30%+47.34%+93.62%

Financials

2024 2025
Net sales - -
Net income -2.02B -12.76M -11.4M -10.47M -9.51M -17.86M -1.21B -18.31M -125M -50.28M -638M -47.89M -46.87M -1.93B -12.17M -10.88M -9.99M -9.07M -17.04M -1.15B -17.47M -119M -47.97M -609M -45.69M -44.71M
Net Debt -8.41B -53.07M -47.41M -43.55M -39.55M -74.28M -5.03B -76.14M -520M -209M -2.65B -199M -195M -6.99B -44.13M -39.43M -36.22M -32.89M -61.77M -4.18B -63.32M -432M -174M -2.21B -166M -162M
Projected Income Statement - Annual - StemRIM
Logo StemRIM
StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.
Employees
-
Date Price Change Volume
02/11/26 JP¥134.00 -3.60% 723,500
30/10/26 JP¥139.00 -4.79% 386,500
29/10/26 JP¥146.00 -0.68% 226,600
28/10/26 JP¥147.00 +2.80% 158,900
27/10/26 JP¥143.00 0.00% 203,500
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - StemRIM

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - StemRIM
  1. Stock Market
  2. Stocks
  3. 4599 Stock